Spending a month in San Francisco is a good way to get out of your head. Some people come to the mountains, where I live, to clear their minds. I like to go where the action is in the city to fill my head with things besides my…
Exposure to certain work- and environment-related elements may be the cause of some idiopathic pulmonary fibrosis (IPF) cases, a recent meta-analysis shows. In particular, exposure to pesticides and agricultural work seem to be factors associated with an increased risk of a person developing IPF. Additionally, exposure to metal dust…
Many diseases have their own awareness color — breast cancer is pink, muscular dystrophy is green, and AIDS is red, for example — but what’s the significance of pink, green, blue, and purple lights side-by-side? These are the colors most often used to represent Rare Disease Day. This…
Respiratory viral and bacterial infections are common in people with idiopathic pulmonary fibrosis (IPF) and might play a role in the development of the disease, a study reported. The study, “The role of viral and bacterial infections in the pathogenesis of IPF: a systematic review and…
People should be reimbursed for costs of using Ofev (nintedanib) to treat progressive fibrosing interstitial lung diseases (PF-ILD), two agencies that help to guide health policy in Canada — the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d’excellence en santé et services sociaux…
The first lung transplant using LUNGguard, a cold storage device for transporting donor lungs, was performed in a person with idiopathic pulmonary fibrosis (IPF), Paragonix Technologies, the device’s developer, announced. The first device of its kind to be cleared by the FDA, it became commercially available…
Last Saturday, Bionews, the parent company of this website, celebrated Rare Disease Day with a virtual event. We planned the event for about 300 participants from the rare disease community who would get together and discuss mental health and chronic illness. They included patients, caregivers, researchers, and…
Cynata Therapeutics will begin a preclinical study to investigate the mechanisms underlying the high potency of its cell therapy, Cymerus mesenchymal stem cells (MSCs), in treating lung diseases such as idiopathic pulmonary fibrosis (IPF). In an earlier study, the investigational therapy was able…
Insilico Medicine announced that it has found a new therapeutic target and potential therapy candidate for idiopathic pulmonary fibrosis (IPF) using artificial intelligence (AI), a company specialty. The potential therapy, a small molecule inhibitor, has been validated in preclinical…
MYMD-1, MyMD Pharmaceuticals’ lead candidate for the treatment of several autoimmune and age-related disorders, showed promising efficacy in targeting the root causes of inflammation in idiopathic pulmonary fibrosis (IPF), according to data from a recent study. The therapy reduced the activity of molecules that are known drivers of…
Get regular updates to your inbox.
